Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.

van de Ven M, van der Burg E, van der Gulden H, Klarenbeek S, Bouwman P, Jonkers J.

J Pathol. 2017 Mar;241(4):511-521. doi: 10.1002/path.4857. Epub 2017 Jan 23.

PMID:
27943283
2.

BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.

Drost R, Dhillon KK, van der Gulden H, van der Heijden I, Brandsma I, Cruz C, Chondronasiou D, Castroviejo-Bermejo M, Boon U, Schut E, van der Burg E, Wientjens E, Pieterse M, Klijn C, Klarenbeek S, Loayza-Puch F, Elkon R, van Deemter L, Rottenberg S, van de Ven M, Dekkers DH, Demmers JA, van Gent DC, Agami R, Balmaña J, Serra V, Taniguchi T, Bouwman P, Jonkers J.

J Clin Invest. 2016 Aug 1;126(8):2903-18. doi: 10.1172/JCI70196. Epub 2016 Jul 25.

3.

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.

Wang Y, Bernhardy AJ, Cruz C, Krais JJ, Nacson J, Nicolas E, Peri S, van der Gulden H, van der Heijden I, O'Brien SW, Zhang Y, Harrell MI, Johnson SF, Candido Dos Reis FJ, Pharoah PD, Karlan B, Gourley C, Lambrechts D, Chenevix-Trench G, Olsson H, Benitez JJ, Greene MH, Gore M, Nussbaum R, Sadetzki S, Gayther SA, Kjaer SK; kConFab Investigators, D'Andrea AD, Shapiro GI, Wiest DL, Connolly DC, Daly MB, Swisher EM, Bouwman P, Jonkers J, Balmaña J, Serra V, Johnson N.

Cancer Res. 2016 May 1;76(9):2778-90. doi: 10.1158/0008-5472.CAN-16-0186.

4.

A high-throughput functional complementation assay for classification of BRCA1 missense variants.

Bouwman P, van der Gulden H, van der Heijden I, Drost R, Klijn CN, Prasetyanti P, Pieterse M, Wientjens E, Seibler J, Hogervorst FB, Jonkers J.

Cancer Discov. 2013 Oct;3(10):1142-55. doi: 10.1158/2159-8290.CD-13-0094. Epub 2013 Jul 18.

5.

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, Klijn C, van der Heijden I, van der Gulden H, Wientjens E, Pieterse M, Catteau A, Green P, Solomon E, Morris JR, Jonkers J.

Cancer Cell. 2011 Dec 13;20(6):797-809. doi: 10.1016/j.ccr.2011.11.014.

6.

Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression.

Bouwman P, Drost R, Klijn C, Pieterse M, van der Gulden H, Song JY, Szuhai K, Jonkers J.

J Pathol. 2011 May;224(1):10-21. doi: 10.1002/path.2861. Epub 2011 Mar 14.

PMID:
21404276
7.

Somatic structural rearrangements in genetically engineered mouse mammary tumors.

Varela I, Klijn C, Stephens PJ, Mudie LJ, Stebbings L, Galappaththige D, van der Gulden H, Schut E, Klarenbeek S, Campbell PJ, Wessels LF, Stratton MR, Jonkers J, Futreal PA, Adams DJ.

Genome Biol. 2010;11(10):R100. doi: 10.1186/gb-2010-11-10-r100. Epub 2010 Oct 13.

8.

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J.

Nat Struct Mol Biol. 2010 Jun;17(6):688-95. doi: 10.1038/nsmb.1831. Epub 2010 May 9.

9.

Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer.

Liu X, Holstege H, van der Gulden H, Treur-Mulder M, Zevenhoven J, Velds A, Kerkhoven RM, van Vliet MH, Wessels LF, Peterse JL, Berns A, Jonkers J.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6. Epub 2007 Jul 11.

10.

Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis.

Derksen PW, Liu X, Saridin F, van der Gulden H, Zevenhoven J, Evers B, van Beijnum JR, Griffioen AW, Vink J, Krimpenfort P, Peterse JL, Cardiff RD, Berns A, Jonkers J.

Cancer Cell. 2006 Nov;10(5):437-49.

11.

Frat is dispensable for canonical Wnt signaling in mammals.

van Amerongen R, Nawijn M, Franca-Koh J, Zevenhoven J, van der Gulden H, Jonkers J, Berns A.

Genes Dev. 2005 Feb 15;19(4):425-30. Epub 2005 Jan 28.

12.

Characterization and functional analysis of the murine Frat2 gene.

van Amerongen R, van der Gulden H, Bleeker F, Jonkers J, Berns A.

J Biol Chem. 2004 Jun 25;279(26):26967-74. Epub 2004 Apr 8.

13.

Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A.

Nat Genet. 2001 Dec;29(4):418-25.

14.
15.

Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2.

van der Lugt NM, Domen J, Verhoeven E, Linders K, van der Gulden H, Allen J, Berns A.

EMBO J. 1995 Jun 1;14(11):2536-44.

16.

Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging.

van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H, Berns A.

Cell. 1991 May 31;65(5):737-52.

PMID:
1904008
17.

Live attenuated pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus protects swine against both pseudorabies and hog cholera.

van Zijl M, Wensvoort G, de Kluyver E, Hulst M, van der Gulden H, Gielkens A, Berns A, Moormann R.

J Virol. 1991 May;65(5):2761-5.

18.

Identification of two genes in the unique short region of pseudorabies virus; comparison with herpes simplex virus and varicella-zoster virus.

van Zijl M, van der Gulden H, de Wind N, Gielkens A, Berns A.

J Gen Virol. 1990 Aug;71 ( Pt 8):1747-55.

PMID:
2167928
19.

Thermodynamic efficiency of bacterial growth calculated from growth yield of Pseudomonas oxalaticus OX1 in the chemostat.

Rutgers M, van der Gulden HM, van Dam K.

Biochim Biophys Acta. 1989 Feb 28;973(2):302-7.

PMID:
2492828
20.

Effect of macromolecular composition of microorganisms on the thermodynamic description of their growth.

Mulder MM, van der Gulden HM, Postma PW, van Dam K.

Biochim Biophys Acta. 1988 Dec 7;936(3):406-12.

PMID:
2461738
21.

Energetic consequences of two mutations in Escherichia coli K+ uptake systems for growth under potassium-limited conditions in the chemostat.

Mulder MM, van der Gulden HM, Postma PW, van Dam K.

Biochim Biophys Acta. 1988 Mar 30;933(1):65-9.

PMID:
3280029
22.

Continued growth of Escherichia coli after stopping medium addition to a K+-limited chemostat culture.

Mulder MM, Van der Gulden HM, Postma PW, Van Dam K.

J Gen Microbiol. 1988 Mar;134(3):777-83.

PMID:
3053977

Supplemental Content

Loading ...
Support Center